I consistently monitor, manage, and improve medical affairs procedures within the organisation. I streamline portfolio development activities within the company through the presentation of strategic medical insights. I deliver expert-level medical support and governance related to various chemical and biological products within the oncology, haematology, cardiology, and autoimmune disorders fields. I establish the best possible regulatory standards by developing SmPCs and PLs. I execute end-to-end activities pertaining to core PV medical writing, such as the preparation of PSURs and RMPs.• Received a promotion from Senior Medical Advisor to Head of Medical Department by showing top-tier performance.• Optimised ease of access to a company's medicinal products via inclusion in reimbursement lists through the provision of scientific and methodological support as per the HTA approach.• Promoted skills improvement among commercial staff and the workforce by organising continuous medical training.• Planned and introduced robust medical affairs standards in strategic and routine corporate functions.• Succeeded in launching seven medical products in oncology, hematology, cardiology fields and immune disorders.

• I oversaw major operations, such as budgeting, personnel recruitment, and local MSL group development. I devised local strategic medical plans and ensured subsequent execution in line with product lifecycle management plans. I coordinated local activities while communicating regularly with regional (CIS and emerging markets) and global functions. I improved engagement via educational programmes, advisory boards, and investigator-initiated studies. I fostered relationships with regional and global medical affairs, regulatory, PV, market access, and patient support functions.• Setup entire medical department of the company, comprising medical affairs (with MSL group), PV, clinical operations, medical QA, and regulatory affairs functions, along with eight direct reports.• Innovated end-to-end contemporary medical affairs activities for unique Rx and OTC products, such as orphan medicines, ADCs (antibody-drug conjugates), and biologics.• Executed product launches for five products in fields of oncology, haematology, gastroenterology, and cardiology.• Built and strengthened relationships with regional and global medical affairs, regulatory, PV, market access, and patient support functions as well as key opinion leaders, whilst improving engagement via educational programmes, advisory boards, and investigator-initiated studies.• Introduced local the system of RWD generation with planning and execution of 1 international observation study, 2 national disease registries support, 4 national surveys of physicians and patients.• Launched 2 investigator-initiated clinical studies in lung cancer and IBD• Enabled organisation to pass various consecutive corporate general and PV audits with minor findings.

I established top-tier compliance and local legislation standards by implementing effective medical governance within the country, covering the approval of promotional, informational, and scientific materials. rendered high-quality guidance on available clinical evidence, contemporary clinical guidelines, and best practice standards related to product portfolios based on universal principles of clinical pharmacology, pharmacoeconomics, health technology assessment, and management. I engaged in regular communication with external experts while delivering development and scientific support.• Planned, rolled out, and supported a medical governance system within the local operating company in line with corporate global policy.• Secured successful launch and reimbursement an innovative target medication in renal cancer• Maximised KOL engagement and facilitated physicians' education by implementing international webinars.• Obtained global corporate support in medical activities for vaccine portfolio in the CIS region, while participating in the organisation of a regional business meeting of vaccine medical affairs staff for further discussion.

• Responsible for health technology assessment & management, with focus on pharmaceuticals, in the teaching regional hospital (1200 beds) & for the health care system of Vitebsk Region (Oblast) serving for 1,2 million inhabitants • New health technologies evaluation and translation, including mini-HTA, pharmacoeconomic and pharmacoepidemiological analyses for drug formulary decisions• Local SOPs maintaining for clinical trials management • Quality assurance of pharmacotherapy care and rational drug use • Expertise in drug information retrieving, evaluation and translation• Clinical consultations on difficult cases of pharmacotherapy in multiprofile hospital settings• National expert under Belarusian Ministry of Health mandate on formulary system development in Belarus

• Lectureship on clinical pharmacology and therapeutics for Belarusian (in Russian) and foreign (in English) medical students, as well as on clinical pharmacology, pharmacoeconomics & HTA for Belarusian health care practitioners• Clinical research on patients’ quality of life and compliance with medications; pharmacoepidemiology and pharmacoeconomics of antihypertensive, antithrombotic drugs and antibiotics; health technology assessment & clinical decision making on pharmacotherapy issues; information and consultation services on rational drug use.

• Consultations of and decision-making for patients with difficult cases of arterial hypertension• Monitoring and management of patients’ quality of life and compliance• Noninvasive monitoring of blood pressure and other hemodynamic parameters • Evaluation & management of arterial compliance and metabolic syndrome

•Teaching preventive medicine and health promotion to university students, with special emphasis on non-communicable metabolic and cardiovascular diseases, HIV infection and drug abuse prevention•Health technology assessment and health outcomes research: clinical, economic and humanistic outcomes of preventive measures and treatment strategies